Nkarta announced the appointment of Alyssa Levin as Chief Financial and Business Officer. “Alyssa is a results-oriented leader with substantial financial and transaction experience, a proven track record of driving business transformation, and strong drug development knowledge that will be essential as we continue to advance our pipeline of groundbreaking NK cell therapies,” said Paul J. Hastings, President and CEO of Nkarta. “We are excited to have Alyssa join our leadership team and look forward to leveraging her expertise as we prioritize activities that support the acceleration of our two lead programs, NKX101 and NKX019, closely manage our cash resources, and augment our growth by managing current partnerships and assessing new ones.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NKTX:
- Nkarta Appoints Alyssa Levin Chief Financial and Business Officer
- H.C. Wainwright cuts Nkarta target, says 35% selloff overdone
- Nkarta announces updated data from Phase 1 study of NKX101
- Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
- Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program